Top 50 Medical Device VC Funds & Investors in Asia (August 2026)
For AI agents: Short investor table (Markdown), Detailed investor list (Markdown)
| Investor | Relevant Deals | Geography | Stage | Focus | Round Size |
|---|---|---|---|---|---|
|
Qiming Venture Partners
VC Fund
|
19 | China, United States, Hong Kong | Series B, Series A, Series C | Health Care, Biotechnology, Medical | $5M–$134M |
|
Cowin Capital
VC Fund
|
13 | China, Hong Kong, United States | Series A, Series B, Seed | Manufacturing, Health Care, Biotechnology | $1.4M–$51M |
|
HSG
VC Fund
|
12 | China, United States, Hong Kong | Series A, Series B, Series C | Health Care, Biotechnology, Software | $4.4M–$214M |
|
Shunwei Capital
VC Fund
|
11 | China, United States, India | Series A, Series B, Series C | Manufacturing, Software, Internet | $1.4M–$130M |
|
Mitsubishi UFJ Capital
VC Fund
|
11 | Japan, United States, Singapore | Series A, Series B | Information Technology, Software, Health Care | $1.2M–$198M |
|
BioVenture
VC Fund
|
11 | China, United States, Hong Kong | Series A, Series B, Seed | Health Care, Medical, Biotechnology | $3.8M–$73M |
|
Taiyu Investment
VC Fund
|
11 | China | Seed, Series A, Angel | Medical, Health Care, Biotechnology | $4.1M–$29M |
|
CD Capital
VC Fund
|
11 | China, United States | Series A, Series B, Seed | Health Care, Biotechnology, Medical Device | $1.4M–$34M |
|
Lilly Asia Ventures
VC Fund
|
10 | China, United States, Hong Kong | Series A, Series B, Series C | Biotechnology, Health Care, Medical | $14M–$308M |
|
BioTrack Capital
VC Fund
|
10 | China, United States, Singapore | Series A, Series B, Seed | Biotechnology, Health Care, Medical | $14M–$168M |
|
UntroD Capital
VC Fund
|
9 | Japan, Singapore, Austria | Seed, Series A | Manufacturing, Biotechnology, Health Care | $772k–$90M |
|
BIOCHING CAPITAL
VC Fund
|
9 | China | Angel, Series A, Seed | Medical, Medical Device, Biotechnology | $425k–$15M |
|
Addor Capital
VC Fund
|
9 | China, Hong Kong, Singapore | Series A, Series B, Seed | Manufacturing, Semiconductor, Electronics | $1.4k–$47M |
|
Haibang Capital
VC Fund
|
9 | China | Series A, Series B, Angel | Health Care, Biotechnology, Manufacturing | $425k–$79M |
|
IDG Capital
VC Fund
|
9 | China, United States, India | Series A, Series B, Series C | Software, Internet, E-Commerce | $3M–$310M |
|
Prox Ventures
VC Fund
|
9 | China, United States, United Kingdom | Seed, Series A | Medical, Biotechnology, Health Care | $2.5M–$28M |
|
EFung Capital
VC Fund
|
8 | China, United States, India | Series B, Series A, Series C | Health Care, Biotechnology, Medical | $1.4M–$100M |
|
Matrix Partners China
VC Fund
|
8 | China, United States, Singapore | Series A, Series B, Seed | Health Care, Software, Artificial Intelligence | $2.8M–$137M |
|
Fast Track Initiative, Inc.
VC Fund
|
8 | Japan, United States, United Kingdom | Series A, Series B, Seed | Health Care, Biotechnology, Medical | $345k–$117M |
|
Dalton Venture
VC Fund
|
8 | China, India, Canada | Seed, Series A, Series B | Health Care, Medical, Biotechnology | $450k–$50M |
|
Med-Fine Capital
VC Fund
|
8 | China, Hong Kong, United States | Series A, Seed, Series B | Medical, Health Care, Biotechnology | $2.8M–$60M |
|
Oriza Seed Capital (Oriza Yuandian)
VC Fund
|
8 | China, United States, Singapore | Series A, Seed, Angel | Manufacturing, Health Care, Medical | $213k–$60M |
|
JAFCO
VC Fund
|
8 | Japan, United States, Israel | Series A, Series B | Information Technology, Software, Artificial Intelligence | $2.1M–$184M |
|
Legend Capital
VC Fund
|
7 | China, United States, South Korea | Series B, Series A, Series C | Health Care, Medical, Biotechnology | $2.9M–$200M |
|
SND Ventures Group
VC Fund
|
7 | China | Series A, Series B, Seed | Manufacturing, Semiconductor, Health Care | $1.4M–$28M |
|
Keio Innovation Initiative
VC Fund
|
7 | Japan, United Kingdom | Series A, Seed | Health Care, Medical, Biotechnology | $826k–$64M |
|
Haiyuan Capital
VC Fund
|
6 | China | Series A, Seed, Angel | Manufacturing, Medical, Semiconductor | $425k–$61M |
|
Highlight Capital
VC Fund
|
6 | China, United States, South Korea | Series A, Series B, Seed | Health Care, Medical, Biotechnology | $2.8M–$84M |
|
SZHTI Group
VC Fund
|
6 | China, United States | Series A, Angel | Manufacturing, Electronics, Semiconductor | $425k–$16M |
|
SBI Investment
VC Fund
|
6 | Japan, South Korea, United States | Series B, Series A | Software, Information Technology, Financial Services | $2.3M–$142M |
|
Marathon Venture Partners
VC Fund
|
6 | China, United States, Hong Kong | Series A, Series B, Seed | Health Care, Medical, Biotechnology | $1.4M–$142M |
|
Shenzhen Capital Group
VC Fund
|
6 | China, United States, Japan | Series A, Series B, Series C | Manufacturing, Health Care, Software | $1.6M–$156M |
|
Mizuho Capital
VC Fund
|
6 | Japan, United States, Singapore | Series A, Series B | Information Technology, Software, Artificial Intelligence | $2M–$269M |
|
Huagai Capital
VC Fund
|
6 | China, United States, Hong Kong | Series A, Series B, Angel | Health Care, Biotechnology, Medical | $425k–$147M |
|
Sunland Fund
VC Fund
|
6 | China | Series A, Series B, Seed | Health Care, Medical, Medical Device | $1.4M–$28M |
|
Oriza Holdings
VC Fund
|
6 | China, United States, Canada | Series A, Series B, Series C | Manufacturing, Health Care, Biotechnology | $1.7M–$200M |
|
Share Capital
VC Fund
|
6 | China, United States, Colombia | Series A, Series B, Seed | Health Care, Medical, Biotechnology | $142k–$93M |
|
Nippon Venture Capital
VC Fund
|
6 | Japan, United States, Indonesia | Series A, Series B | Software, Health Care, Information Technology | $1.5M–$269M |
|
ANRI
VC Fund
|
5 | Japan, United States, Indonesia | Seed, Series A | Software, Medical, Health Care | $413k–$41M |
|
CDH Investments
VC Fund
|
5 | China, United States, Canada | Series A, Series B, Series C | Manufacturing, Health Care, Biotechnology | $7.3M–$220M |
|
Fortune Venture Capital
VC Fund
|
5 | China, Japan, United States | Series A, Series B, Seed | Manufacturing, Software, Information Technology | $425k–$73M |
|
Apricot Capital
VC Fund
|
5 | China, United States, Hong Kong | Series A, Seed, Series B | Biotechnology, Health Care, Medical | $3M–$58M |
|
UTEC - The University of Tokyo Edge Capital Partners
VC Fund
|
5 | Japan, United States, India | Seed, Series A, Series B | Health Care, Biotechnology, Medical | $2.5M–$100M |
|
Tsinghua Innovation Ventures
VC Fund
|
5 | China | Series A, Seed | Manufacturing, Medical, Health Care | $832k–$23M |
|
Seeds Capital
VC Fund
|
5 | Singapore, United States, Hong Kong | Seed, Series A, Series B | Biotechnology, Artificial Intelligence, Health Care | $767k–$45M |
|
Nissay Capital
VC Fund
|
5 | Japan, United States, Ethiopia | Seed, Series A | Health Care, Information Technology, Medical | $565k–$71M |
|
Huaige Capital
VC Fund
|
5 | China | Series A, Angel, Seed | Medical, Health Care, Biotechnology | $425k–$36M |
|
Northern Light Venture Capital
VC Fund
|
5 | China, United States, South Korea | Series A, Series B, Seed | Health Care, Medical, Biotechnology | $1.3M–$100M |
|
FFG Venture Business Partners
VC Fund
|
5 | Japan, Indonesia, United States | Series A, Seed, Series B | Software, Health Care, Artificial Intelligence | $1M–$113M |
|
Green Pine Capital Partners
VC Fund
|
4 | China, United States, Canada | Series A, Angel, Series B | Artificial Intelligence, Biotechnology, Health Care | $425k–$150M |
| Access all 50 VC funds in Asia Medical Device startups. | |||||
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!Investor list
Founded in 2006, Qiming Venture Partners is a leading China venture capital firm with offices in Shanghai, Beijing, Suzhou, Hong Kong in China, and Singapore.Currently, Qiming Venture Partners manages eleven US Dollar funds and seven RMB funds with $9.5 billion in capital raised. Since our establishment, we have invested in outstanding companiesin the Technology and Consumer (T&C) and Healthcare industries at the early and growth stages.Since our debut, we have backed over 530 fast-growing and innovative companies. Over 200 of our portfolio companies have achieved exits through IPOs at the NYSE, NASDAQ, HKEX, Shanghai Stock Exchange, or Shenzhen Stock Exchange, or through M&A or other means. There are also over 70 portfolio companies that have achieved unicorn or super unicorn status.
Show more...Investment focus
- Industry: Health Care, Biotechnology, Medical
- Stage:Series B, Series A, Series C
- Geography: China, United States, Hong Kong
Investor stats
- Total investments: 898
- Round size: Series A $5M–$67M; Series B $9.4M–$100M; Series C $15M–$134M
- Lead/follow: 45% lead, 55% follow
- Last fund: Likely still investing — raised $887M in 2023
Portfolio highlights
- Guangjing Energy — Guangjing Energy specializes in the R&D and mass production of durable, large-area perovskite solar cell modules. They develops perovskite film printing technology with independent intellectual property rights and realized the preparation of large-area perovskite components.
- Talaris Therapeutics — Talaris seeks to help kidney transplant recipients and patients suffering from severe auto-immune diseases to live healthy lives free from chronic immunosuppression
- Shennapsi Artificial Intelligence Technology — Synapsor is a medical-grade wearable device research and development company, oriented to the AI+ medical and health field, and is committed to the development and manufacturing of AI-powered medical-grade smart wearable devices, including AI-ECG artificial intelligence. Diagnostic analysis system, CUMS uric acid blood glucose and cholesterolmonitoring system, etc. The company has recently received tens of millions of yuan in Series B investment, and the investor is Xiaomi Technology.
Cowin Capital is a private placement equity investment company focusing on investing in a pioneering enterprise on a long-term basis. It has 18 years of experience in capital management, whose capital management scale was among the front rank, which invested more than 300 companies, of which 60 more became public companies, and 150 moresuccessfully exit.The company was successfully listed on NEEQ, with code 832793, as the third listed famous domestic venture capital institution in NEEQ. It is committed to supporting the growth of small and medium enterprises, continue to launch high-quality listed companies in China Capital Market.
Show more...Investment focus
- Industry: Manufacturing, Health Care, Biotechnology
- Stage:Series A, Series B, Seed
- Geography: China, Hong Kong, United States
Investor stats
- Total investments: 327
- Round size: Seed $1.4M–$20M; Series A $4.3M–$51M; Series B $2.8M–$50M
- Lead/follow: 47% lead, 53% follow
- Last fund: May invest from a new fund soon — raised $75M in 2014
Portfolio highlights
- Bytetree — Bytetree is a technology company that focuses on providing the one-stop AI data services for data collection, cleaning, labeling, management, and storage for OEMs and autonomous driving solution providers, covering bicycle intelligence. , vehicle-road coordination, and smart cockpit three scenarios.
- Digital China — Digital China is a robotics company focused on developing humanoid interactive robots that can break traditional boundaries and create emotionally resonated partners.
- Huachen Core Light — Huachen Core Light is a semiconductor technology company that produces and manufactures optical communications and laser chips.
We help founders build enduring companies.
Show more...Investment focus
- Industry: Health Care, Biotechnology, Software
- Stage:Series A, Series B, Series C
- Geography: China, United States, Hong Kong
Investor stats
- Total investments: 751
- Round size: Series A $4.4M–$100M; Series B $12M–$200M; Series C $26M–$214M
- Lead/follow: 42% lead, 58% follow
- Last fund: Likely still investing — fund raised in 2024
Portfolio highlights
- MarqVision — Effortlessly discover and remove counterfeits to protect your sales and reputation.
- Midas — Midas is the first neobroker of Turkey, providing zero commission Turkish and American stocks.
- Yunzhou Zhiwei — Yunzhou Zhiwei is a high-tech startup focused on serving large-scale equipment maintenance industries such as aviation, aerospace, shipbuilding, and rail transit. It leverages smart maintenance concepts and advanced digital technologies to make complex equipment maintenance more efficient and lean. The company drives industrial transformationtoward intelligent maintenance, helping enterprises enhance growth, efficiency, and operational excellence.
Shunwei Capital is a venture capital fund that focuses on early to mid-stage investments in local internet industry. It specializes in incubation, startups, early to mid-stage, and growth capital investments. It seeks to invest in the technology, media, telecommunications, high technology, new media, games, internet finance, and rural area internetsectors. Their investors include sovereign wealth funds, fund of funds, university endowment funds, and family offices.
Show more...Investment focus
- Industry: Manufacturing, Software, Internet
- Stage:Series A, Series B, Series C
- Geography: China, United States, India
Investor stats
- Total investments: 488
- Round size: Series A $1.4M–$41M; Series B $8.2M–$58M; Series C $25M–$130M
- Lead/follow: 32% lead, 68% follow
- Last fund: May invest from a new fund soon — raised $1.2B in 2018
Portfolio highlights
- Z.ai — The AI Lab behind GLM models, dedicated to inspiring the development of AGI to benefit humanity. https://t.co/7a5aSCUfnr https://t.co/x14hb3jO7O
- Darma — DARMA - Digital Healt
- Heluo New Image — Heluo New Image is a cell treatment platform developer that focuses on iPSC directed differentiation, gene editing, large-scale cell product production, and cell therapy technology development.
Mitsubishi UFJ Capital is a venture capital firm focusing on life science, ICT, and high technology investments.
Show more...Investment focus
- Industry: Information Technology, Software, Health Care
- Stage:Series A, Series B
- Geography: Japan, United States, Singapore
Investor stats
- Total investments: 576
- Round size: Series A $1.2M–$74M; Series B $4.3M–$198M
- Lead/follow: 5% lead, 95% follow
- Last fund: May invest from a new fund soon — raised $1.4B in 2020
Portfolio highlights
- ADiXi — Adixi is a tech-driven business that supports the idea that people and technology may work together. It strives to open doors by utilizing cutting-edge technology, such as artificial intelligence, to promote long-term, sustainable corporate and societal progress.
- WARPSPACE — ARPSPACE is a space startup originating from the University of Tsukuba, has been launching and working on a satellite development project at the University of Tsukuba for five years until the company was established.
- Luxna Biotech — Luxana Biotech is a biotechnology firm dedicated to promoting the practical use of safe and effective nucleic acid therapies. Utilizing nucleic acid chemistry technology, the company strives to provide nucleic acid medicines to patients suffering from diseases that currently lack effective treatments.
Suzhou Industrial Park Bioventure Investment Management Limited (Bioventure) was established in September 2013. Bioventure its first element of the new bio-industry funds 540 million yuan fund size. Bioventure specialize in the field of life sciences in the early stages of the venture capital investments as having high strength and growth, greaterdevelopment space, excellent management team, biotechnology, drug discovery, medical devices and healthcare services companies, and provide capital, management , operation and other aspects of post-investment support and services.Bioventure brought together senior investment professionals team with bio-pharmaceutical industry investment experience, strong fund management, entrepreneurship and venture capital and operating experience in business, have a deep understanding of the domestic and foreign markets, capable of its forward-looking international perspective and extensive The industry has the potential resources to help innovative companies grow rapidly and gain greater success, while giving fund investors bring considerable returns.Suzhou Industrial Park, the core investor BioBay has the country's best medical and pharmaceutical incubator function, use the platform, the project team has great resources and industrial service advantages, Yuan-sheng venture has successfully invested in 20 projects have been cast projects in their own development and follow-up financing, has made outstanding achievements in the industry for all to see, and won the Venture's trust and praise.By focusing and extensive industry resources, Bioventure determined to become one of China's most successful medical and pharmaceutical venture fund. Bioventure expectations and in the medical and pharmaceutical industry where there joint venture development cooperation.
Show more...Investment focus
- Industry: Health Care, Medical, Biotechnology
- Stage:Series A, Series B, Seed
- Geography: China, United States, Hong Kong
Investor stats
- Total investments: 171
- Round size: Seed $7.9M–$41M; Series A $3.8M–$47M; Series B $7.1M–$73M
- Lead/follow: 35% lead, 65% follow
Portfolio highlights
- Dami&Xiaomi — Rice and millet is China's leading platform services for children with autism spectrum, from 2014 Nian 9 Yue Jiang Ying Shuang (rice) founded the "rice and millet" micro-channel public number. It now provides integrated services such as rehabilitation services, integrated education support, parent training, online courses, andpopular science information.
- CART Medical — CART Medical Technologies, Ltd. is a high-tech company specializing in the development and application of new technologies for immune cell therapy. It has a 2,200 square meter GMP laboratory and research and development laboratory.
- MyoGene Life Sciences — MyoGene Life Sciences is a regenerative medical company that specializes in the promotion of its regenerative repair material product line for bone repair.
Taiyu Investment is an investment firm.
Show more...Investment focus
- Industry: Medical, Health Care, Biotechnology
- Stage:Seed, Series A, Angel
- Geography: China
Investor stats
- Total investments: 43
- Round size: Seed $4.1M–$20M; Series A $13M–$29M
- Lead/follow: 21% lead, 79% follow
Portfolio highlights
- Immunocan — JAWA138 memimpin di garis depan Inovasi Sistem Permainan Digital dengan fokus pada transparansi dan keadilan, terutama melalui Mekanisme RTP (Return to Player) yang Akurat.
- Rhino Medical — Rhino Medical develops advanced technologies with independent intellectual property rights. The founding team has rich experience in R&D, marketing, and clinical. On the basis of benchmarking imported phacoemulsification instruments and vitrectomy instruments
- Infineon Multiomics — Infineon Multiomics is a biotechnology company that provides research and application of space multiomics technology.
CD Capital is a venture capital firm specialized in life sciences and medical technology. They are currently managing both RMB and USD funds with total size of $600M. CD Capital is operated by a professional team with diversified and profound industry backgrounds. They have made over 40 investments with high growth potential and earned a reputationas a premier venture capital firm with main focus on China healthcare industry. With broad network around China and the world, they have been able to seize the global trend, capture investment opportunities as well as help to define the future for China healthcare industry. Ultimately, they strive to grow best-in-class companies and deliver solid financial return to their investors.
Show more...Investment focus
- Industry: Health Care, Biotechnology, Medical Device
- Stage:Series A, Series B, Seed
- Geography: China, United States
Investor stats
- Total investments: 73
- Round size: Seed $1.4M–$15M; Series A $1.4M–$32M; Series B $7.1M–$34M
- Lead/follow: 37% lead, 63% follow
Portfolio highlights
- Genlight — Genlight develops innovative treatment solutions for epilepsy and other neurological diseases. Genlight is headquartered in Hangzhou, China.
- Pipi Bear — Pipi Bear is a creator of living robots and health goods, with a focus on those that improve the lives of the elderly.
- CORE Biomedicine — CORE Biomedicine is a private, preclinical-stage biotechnology company that specializes in drug discovery and development for oncology.
Lilly Asia Ventures (LAV) is a leading biomedical venture capital firm headquartered in China, with offices in Shanghai, Hong Kong, and Palo Alto.
Show more...Investment focus
- Industry: Biotechnology, Health Care, Medical
- Stage:Series A, Series B, Series C
- Geography: China, United States, Hong Kong
Investor stats
- Total investments: 221
- Round size: Series A $14M–$100M; Series B $25M–$110M; Series C $30M–$308M
- Lead/follow: 25% lead, 75% follow
- Last fund: May invest from a new fund soon — raised $40M in 2019
Portfolio highlights
- Passage Bio — Passage Bio, a genetic medicines company, is changing the future of CNS disorders and transforming the lives of patients and their families.
- ProfoundBio — ProfoundBio is an oncology biotherapeutics company focused on the development of novel antibody-based therapeutics with curative potential for patients with cancer.
- Abogen Biosciences — Abogen Biosciences is a discovery stage biotechnology company focuses on developing nucleic acid-based (RNA and DNA) therapeutics for treatment of cancer and infectious diseases.
BioTrack Capital invests in early and growth stage companies within life sciences, healthcare technology, biotechnology and related high-tech sectors, providing capital and investment support for innovation. The firm evaluates scientific and commercial potential of ventures and structures financings aimed at advancing technologies from earlyresearch to market engagement. Its activities include sourcing opportunities, conducting due diligence, and working with founders and management teams to align growth strategies with investor objectives. BioTrack Capital also participates in funding rounds alongside co-investors to support development of novel healthcare and tech solutions. The company engages with portfolio companies through strategic interaction and monitoring of progress toward business milestones.
Show more...Investment focus
- Industry: Biotechnology, Health Care, Medical
- Stage:Series A, Series B, Seed
- Geography: China, United States, Singapore
Investor stats
- Total investments: 93
- Round size: Seed $16M–$168M; Series A $14M–$45M; Series B $15M–$147M
- Lead/follow: 32% lead, 68% follow
Portfolio highlights
- Huihe Healthcare — Huihe Healthcare specializes in the development of medical devices for structural heart disease. The company was founded in 2019 and is headquartered in Shanghai, China.
- LaNova Medicines — LaNova Medicines is a clinical-stage innovative drug research and development company. The company focuses on the unmet therapeutic needs in the field of tumor immunity and tumor microenvironment and focuses on the research and development of "world's first" and "best-in-class" potential bio-innovative drugs.
- Zhiyue Space Intelligence — Zhiyue Space Intelligence specializes in robotic brain and brain systems.
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!UntroD Capital is an R&D-based innovative technology that specializes in social implementation.
Show more...Investment focus
- Industry: Manufacturing, Biotechnology, Health Care
- Stage:Seed, Series A
- Geography: Japan, Singapore, Austria
Investor stats
- Total investments: 138
- Round size: Seed $772k–$28M; Series A $2.3M–$90M
- Lead/follow: 40% lead, 60% follow
- Last fund: Likely still investing — fund raised in 2024
Portfolio highlights
- CastBio — Castbio specializes in antibody-drug conjugate-based drug discovery research and development. Along with medications, it also creates research reagents, medical equipment, in vitro diagnostic items, and offers drug discovery consulting.
- Eco-Pork — Eco-Pork is a co-creation solution farm that supports farmers' food productivity improvement. It is connecting the pig and technology, pork ( Pork ) new business ecosystems ( Ecosystem By building a), in the pork growing demand around the world, to get the most out of the food supply capacity is finite.
- IGrid Solutions — IGrid Solutions will promote “eDCM” to optimize power energy demand.
BIOCHING CAPITAL is an investment management firm.
Show more...Investment focus
- Industry: Medical, Medical Device, Biotechnology
- Stage:Angel, Series A, Seed
- Geography: China
Investor stats
- Total investments: 20
- Round size: Angel $425k–$15M; Series A $14M–$14M
- Lead/follow: 20% lead, 80% follow
Portfolio highlights
- Lunke Medical — Lunke Medical focuses on the research, development, production, and sales of medical devices, with particular strength and expertise in high-pressure technologies. The company is committed to delivering safe, reliable, and innovative solutions by combining advanced engineering, strict quality control, and continuous technological advancement tomeet the evolving needs of the medical industry.
- Taose Tuantuan — Taose Tuantua is a sex toy company that primarily offers TAOSETT sex toy academy and exquisite sex toy community store services.
- Qinglan Jichuang — Qinglan Jichuang is a domestic high-performance intelligent endoscope innovative enterprise.
Addor Capital offers investment services by financing early stage ventures and holding securities of other companies.
Show more...Investment focus
- Industry: Manufacturing, Semiconductor, Electronics
- Stage:Series A, Series B, Seed
- Geography: China, Hong Kong, Singapore
Investor stats
- Total investments: 344
- Round size: Seed $1.4k–$14M; Series A $1.6M–$43M; Series B $13M–$47M
- Lead/follow: 50% lead, 50% follow
Portfolio highlights
- Ibeki — Ibeki provides tiny photoelectric displacement sensors and servo control systems. eBridge uses the high precision and miniaturization of its precision motion drive technology to provide customers with a more complete technology portfolio, and has successfully transformed its core technology into a number of military and civilian products,particularly in aerospace, medical equipment, and intelligent control.
- Beta Infinite — Beta Infinite approaches data and model technologies in a distinctive and distinctive way.
- Ruimeng Semiconductor — Ruimeng Semiconductor is a provider of intelligent human-machine interface processor chips and solutions.
Zhejiang Haibang Investment Management Co., Ltd. (also referred as "Haibang Capital") is an investment company focusing on venture capital and private equity. It was established in 2011 in Hangzhou. It was founded by Naxin Yao, the CEO of Focused Photonics, Inc (300203), a number of returnee entrepreneurs and experienced investmentprofessionals. In 2011, Haibang Capital launched its first Haibang Fund (formerly called “Haibang Talent Fund”) which was the first venture capital in China helping new returnees to start their own businesses. It is also a fund connect capital and "Thousand Talent Program" in Zhejiang Province. Haibang Capital keeps working on helping enterprises grow rapidly and build leading edge in their industry. In addition to providing capitals, Haibang Capital provides its investee companies with personalized value-added services, helping create both good economic and social benefits.
Show more...Investment focus
- Industry: Health Care, Biotechnology, Manufacturing
- Stage:Series A, Series B, Angel
- Geography: China
Investor stats
- Total investments: 48
- Round size: Angel $425k–$2.8M; Series A $1.4M–$15M; Series B $10M–$79M
- Lead/follow: 21% lead, 79% follow
Portfolio highlights
- Wuwen Zhike — Wuwen Zhixing is an intelligent driving service provider dedicated to offering professional and cutting-edge integrated solutions for AI data and simulation verification, as well as developing AI data infrastructure and accelerators.
- Hopstem — Hopstem is a Hangzhou-based pharmaceutical company, engaged in human iPSCs/ESCs neural differentiation, cell banking, and cell engineering.
- Hongde New Materials — Hongde New Materials produces thermoplastic composite materials with fiber reinforcement. It offers energy storage and auxiliary components for solar and automobile power and steering systems.
IDG Capital is a global investment firm partnering with founders to build enduring businesses through capital, expertise, and long-term support.
Show more...Investment focus
- Industry: Software, Internet, E-Commerce
- Stage:Series A, Series B, Series C
- Geography: China, United States, India
Investor stats
- Total investments: 826
- Round size: Series A $3M–$122M; Series B $8.5M–$142M; Series C $15M–$310M
- Lead/follow: 34% lead, 66% follow
- Last fund: May invest from a new fund soon — last raise in 2017
Portfolio highlights
- Hypershell — An exoskeleton innovator reshaping lifestyles and enabling technology to empower life.
- Bivision — Biovision Pharma is a biomedical enterprise focusing on the research and development of targeted radiopharmaceuticals (TRT) integrated with visual diagnosis and treatment.
- Youxi Film Hotel — Youxi Film Hotel which is a hotel in China that combines the perfect combination of hotel and movie IP. It is also a movie hotel theme, combining film derivative industry, movie theme social space and film shooting. An integrated creative culture complex; dedicated to creating a Chinese-style movie and hotel cross-border experience hotel, breakingthrough the traditional overnight function of a traditional hotel, creating the ultimate movie experience for young people with a mindset.
Proxima Ventures focuses in the healthcare industry, supporting outstanding enterprises with innovative technologies or service models that have tremendous potential.They manage multiple funds in RMB and US dollar, covering from seed to growth stages. Their team members with multidisciplinary backgrounds and resourceful networks, have many yearsof remarkable venture capital experience and achievements. They believe that active and effective collaboration with entrepreneurs will make substantial economic returns while bring meaningful improvements in public health.
Show more...Investment focus
- Industry: Medical, Biotechnology, Health Care
- Stage:Seed, Series A
- Geography: China, United States, United Kingdom
Investor stats
- Total investments: 81
- Round size: Seed $2.5M–$14M; Series A $2.8M–$28M
- Lead/follow: 19% lead, 81% follow
Portfolio highlights
- Shengxin Medical — Shengxin Medical is a cardiovascular interventional medical device developer, dedicated to creating innovative, high-quality solutions that improve the diagnosis, treatment, and management of cardiovascular diseases, while advancing minimally invasive medical technologies to enhance patient outcomes and clinical efficiency.
- Bluesail Surgical — Bluesail Surgical is a surgical device company that specializes in the development of innovative surgical instruments for cardiovascular and cerebrovascular treatments.
- Kingsung Medical Group — Kingsung Medical Group operates under the Mission “Simplify Surgery, Beautiful Life,” with its innovation centered on four core technology platforms at its Tianjin base: Mechanical Design, Polymer Materials, Biodegradable Magnesium Alloys, and Collagen Biomaterials. These platforms have enabled the development of pioneering medical devices,including microvascular anastomosis devices and neural tube. In particular, the Group’s biodegradable magnesium alloy technology is spearheading the advancement of next-generation orthopedic implants. Kingsung’s technological capabilities are evidenced by a portfolio of over 190 patents and its recognition as a National Key Enterprise. The Group also actively contributes to the industry as a standing council member of the Microsurgery Branch of the China Association of Medical Devices Industry and a member of the Chinese Society for Biomaterials.
Shenzhen EFUNG Investment Management Enterprise L. P. is one of China's earliest institutions investing in professional biomedical industries. Their strong research team and great investment returns made us won 'The Most Pioneering VC Institution” 'The Most Dynamic Pharmaceutical VC Institution in China' and 'The Top Ten VCInstitutions in Shenzhen'. With this influence, EFUNG has drawn a lot of attention from the medical and life science industry. And it is interviewed by Nature, which is the most authoritative science magazine in the world. Over a decade of years, they have been focusing on the medical and health industry, especially the VC and PE investment business of novel drugs and high-end medical devices. The mission of EFUNG is to drive the industrialization of medical researches by capital and to gain rich returns to investors. EFUNG has deeply screened and invested in more than 20 domestic and international premium enterprises, such as Chipscreen Biosciences, Frontier Biotechnologies, Ascentage Pharma, Lifotronic, Aridis Pharmaceuticals, and Centrexion.
Show more...Investment focus
- Industry: Health Care, Biotechnology, Medical
- Stage:Series B, Series A, Series C
- Geography: China, United States, India
Investor stats
- Total investments: 82
- Round size: Series A $1.4M–$36M; Series B $14M–$100M; Series C $14M–$74M
- Lead/follow: 35% lead, 65% follow
Portfolio highlights
- Yuewei Medical — Yuewei Medical is a developer of cardiac surgery interventional medical devices.
- Heluo New Image — Heluo New Image is a cell treatment platform developer that focuses on iPSC directed differentiation, gene editing, large-scale cell product production, and cell therapy technology development.
- Xgene Pharmaceutical — Xgene Pharmaceutical is a pharmaceutical company.
Matrix Partners China builds long-term relationships with entrepreneurs and helps them build significant, industry-leading companies.Since its inception in 1977, Matrix Partners China has made hundreds of investments and played an active role in the development of many successful businesses, 50 of which went on to IPO, and 75 of which have goneon to profitable M&A events. The firm consistently ranks in the top venture firms in terms of returns to its investors.Matrix Partners China combines local knowledge with global experience and vision. Its team consists of both former entrepreneurs and experienced investors. Its past successes include Focus Media, Eachnet, and Baidu, among others. The company invests across multiple sectors and stages.
Show more...Investment focus
- Industry: Health Care, Software, Artificial Intelligence
- Stage:Series A, Series B, Seed
- Geography: China, United States, Singapore
Investor stats
- Total investments: 498
- Round size: Seed $2.8M–$98M; Series A $3M–$61M; Series B $10M–$137M
- Lead/follow: 34% lead, 66% follow
Portfolio highlights
- Lexin — LexinFintech Holdings is an online consumer finance platform for educated young adults in China. As one of China's leading financial technology companies, Lexin integrates its e-commerce-driven installment finance platform, Fenqile, with advanced risk management technologies, the Company's Dingsheng online investment platform, and theCompany's Juzi Licai online investment platform for individual investors, to create a comprehensive consumer finance ecosystem. The Company utilizes technologies including big data, cloud computing and artificial intelligence to enable the near-instantaneous matching of user funding requests with offers from the Company's more than 30 funding partners, which include commercial banks, consumer finance companies, and other licensed financial institutions. By serving the credit needs of China's educated young adults, Lexin helps its more than 20 million registered users to enjoy a better quality of life through the use of better credit.
- Camera360 — Camera360 is a professional but easy-to use App for photo editing and selfie retouching. Tag #camera360
- Liepin — Liepin is the largest and most professional high-end talent community-based recruitment site, with its innovative products and unique service model model for create an interactive high-end talent recruitment platform between business, headhunting and workplace. Tens of thousands of professional executive search consultant for businesses and jobseekers set up communication between the bridge and accelerate corporate recruitment process, recommended paying jobs in the workplace, career development planning. 16 job seekers to avoid the risk of privacy protection, millions of high-end elite member libraries, help enterprises development needs.
Fast Track Initiative is a venture capital firm with an exclusive focus on life sciences and healthcare services.
Show more...Investment focus
- Industry: Health Care, Biotechnology, Medical
- Stage:Series A, Series B, Seed
- Geography: Japan, United States, United Kingdom
Investor stats
- Total investments: 83
- Round size: Seed $345k–$117M; Series A $3M–$113M; Series B $9.5M–$91M
- Lead/follow: 28% lead, 72% follow
- Last fund: May invest from a new fund soon — raised $1.1B in 2021
Portfolio highlights
- NovAccel — NovAccel operates as a deep tech company, ensure a stable supply of medical radioisotopes.
- Storm Therapeutics — Targeting pathways that modify RNA to deliver novel cancer therapeutics.
- Neusignal Therapeutics — Neusignal Therapeutics is a medical company that develops therapeutic medicines for dementia and psychiatric illnesses.
Dalton Venture is a fund management company that specializes in early stage investment and industrial mergers and acquisitions in the field of big health.
Show more...Investment focus
- Industry: Health Care, Medical, Biotechnology
- Stage:Seed, Series A, Series B
- Geography: China, India, Canada
Investor stats
- Total investments: 142
- Round size: Seed $450k–$5M; Series A $2.8M–$17M; Series B $2.8M–$50M
- Lead/follow: 37% lead, 63% follow
Portfolio highlights
- PowerMicro — PowerMicro focuses on the cutting-edge interdisciplinary field of “stem cells + engineered scaffolds,” specializing in the application of iPSC technology to advance regenerative medicine, tissue engineering, and innovative therapeutic solutions.
- NewPro — NewPro is in the process of increasing production and establishing regulations for lactoferrin raw materials, with the goal of bringing the product to market as quickly as feasible.
- Active Technology — Active Technology is a pioneering deep tech startup specialized in developing invasive brain computer interface (BCI) technology. The company integrates flexible electrodes, dedicated chips, and advanced decoding algorithms to target motor, visual, and emotional neural pathways.
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!Med-Fine Capital is a venture capital firm focusing on early stage investments in China healthcare industry. The company is headquartered in Shanghai with offices in Beijing and Shenzhen.
Show more...Investment focus
- Industry: Medical, Health Care, Biotechnology
- Stage:Series A, Seed, Series B
- Geography: China, Hong Kong, United States
Investor stats
- Total investments: 83
- Round size: Seed $8M–$60M; Series A $2.8M–$40M; Series B $11M–$60M
- Lead/follow: 31% lead, 69% follow
- Last fund: May invest from a new fund soon — raised $69M in 2019
Portfolio highlights
- Zhuanma Biotech — Zhuanma Biotechnology is a gene editing service provider dedicated to clinically developing effective ultra-small gene editors into genetic therapeutics that are "curable once and for all."
- Tianyikang Biotechnology — Tianyikang Biotechnology focuses on medical research and the development and application of next-generation cell immunotherapy products.
- Beijing Ansong Technology — Beijing Ansong Technology Co., Ltd. is an enterprise focusing on the research and development, production, and sales of orthopedic medical devices. The company cooperates with domestic and foreign universities, research institutes, and doctors in hospitals, and is committed to creating original orthopedic products with independent knowledgeproducts.Beijing Ansong Technology was founded on June 27, 2011 by Liang Tao in Fengtai, Beijing.
Oriza Seed Venture Capital, located in Suzhou Industrial Park, is held by Suzhou Oriza Holdings Ltd. Oriza Seed is a market-oriented investment platform. It looks for investment opportunities among early-stage and growth-stage enterprises in the fields of Healthcare and TMT. Oriza Seed has ample resources and experiences investing in the healthcarefield. By late March 2016, Oriza Seed has invested in more than 50 healthcare companies, including Ascentage Pharma, Innovent Biologics, and SceneRay Corporation.
Show more...Investment focus
- Industry: Manufacturing, Health Care, Medical
- Stage:Series A, Seed, Angel
- Geography: China, United States, Singapore
Investor stats
- Total investments: 149
- Round size: Seed $213k–$25M; Angel $425k–$14M; Series A $1.4M–$60M
- Lead/follow: 28% lead, 72% follow
Portfolio highlights
- Youshu Quantum — Youshu Quantum is a deep-tech startup specializing in quantum computing software, middleware, and proprietary algorithms.
- Jitian Xingzhou — Jitian Xingzhou is a commercial aerospace company that provides optical main payloads in batches as one of its primary operations.
- Huihe Healthcare — Huihe Healthcare specializes in the development of medical devices for structural heart disease. The company was founded in 2019 and is headquartered in Shanghai, China.
Since its founding in 1973, JAFCO has always worked with leading-edge entrepreneurs. The total capital commitments of its investment funds in Japan and overseas have exceeded 1 trillion yen and the number of portfolio IPOs to date has reached over 1,000. In addition to venture investment, JAFCO also carries out buyout investment and commit to thecreations of innovative technologies and services worldwide. As entrepreneurs’ closest partner in bringing their visions to life, JAFCO provides support in areas of HR, marketing/ sales, and back-office operations, in addition to providing financing.
Show more...Investment focus
- Industry: Information Technology, Software, Artificial Intelligence
- Stage:Series A, Series B
- Geography: Japan, United States, Israel
Investor stats
- Total investments: 304
- Round size: Series A $2.1M–$142M; Series B $6.4M–$184M
- Lead/follow: 29% lead, 71% follow
- Last fund: May invest from a new fund soon — last raise in 2019
Portfolio highlights
- ADiXi — Adixi is a tech-driven business that supports the idea that people and technology may work together. It strives to open doors by utilizing cutting-edge technology, such as artificial intelligence, to promote long-term, sustainable corporate and societal progress.
- Alxtal — Alxtal is a tech company who optimize the development, design, and manufacturing processes of the manufacturing industry with IT and AI.
- Yokohama Vanilla — Yokohama Vanilla is a Company which operates Yokohama-based gift sweets brand.
Legend Capital, a subsidiary of Legend Holdings Ltd., started its vintage year in April, 2001 with a mission to become a top-notch and the most respected venture capital investment manager in China.Managing up to US$700 million across four funds, Legend Capital focuses on driving high-growth ventures with operations substantially based in Chinaor on markets related to China.Legend Capital mainly invests in early stage IT companies, specifically, in sectors of network applications and services, outsourcing and professional services, Infrastructure (IC design/key components), and mid-market growth stage companies in the fields of consumer goods, clean technology, health care, equipment manufacturing and modern services.Among over 60 portfolio companies are Joyo.com (acquired by Amazon.com), SinoCom (0299.HK), Solarfun Power (Nasdaq: SOLF), Spreadtrum Communications (Nasdaq: SPRD), China Sunshine Paper (2002.HK), and VanceInfo (NYSE:VIT), Eyang (0117.HK), etc.As an active investor, Legend Capital provides its portfolio companies extensive business resources and tailored services to assist with business development, company image building, and other critical company building activities on Chinese market so as to add value and maximize returns. Legend Capital is proud and thankful that it has the opportunity to blaze a trail with its innovative practice for China's venture capital industry.
Show more...Investment focus
- Industry: Health Care, Medical, Biotechnology
- Stage:Series B, Series A, Series C
- Geography: China, United States, South Korea
Investor stats
- Total investments: 427
- Round size: Series A $2.9M–$100M; Series B $12M–$115M; Series C $15M–$200M
- Lead/follow: 39% lead, 61% follow
- Last fund: Likely still investing — raised $177M in 2021
Portfolio highlights
- Z.ai — The AI Lab behind GLM models, dedicated to inspiring the development of AGI to benefit humanity. https://t.co/7a5aSCUfnr https://t.co/x14hb3jO7O
- Pony.ai — Pony.ai is a startup that builds full-stack autonomous driving solutions. It is a pioneer in autonomous mobility technologies and services across the US and China, spearheading public-facing Robotaxi pilots in both markets. Pony.ai is committed to creating a safe and sustainable mobility future by delivering autonomous mobility everywhere.Thecompany was founded by James Peng and Tiancheng Lou in 2016 and is headquartered in Fremont, California, United States.
- Jinqirui Biology — Jinqirui Biology is a biotechnology company that focuses on the research and development, manufacturing, production & sales of vitro diagnostics equipment and reagents.
SND Ventures Group is a venture capital and private equity firm specializing in seed investments.
Show more...Investment focus
- Industry: Manufacturing, Semiconductor, Health Care
- Stage:Series A, Series B, Seed
- Geography: China
Investor stats
- Total investments: 84
- Round size: Series A $1.4M–$21M; Series B $1.4M–$28M
- Lead/follow: 21% lead, 79% follow
Portfolio highlights
- Ruiqi Deep Space — Ruichi Deep Space is an intelligent remote sensing constellation company built on space-based capabilities and driven by AI , aiming to construct a " commercial aerospace" platform.
- Jipai Electromagnetic — Jipai Electromagnetic specializes in the manufacture of automobile components and accessories.
- Sicui Thermal Control — Sicui Thermal Control focuses on the design of next-generation semiconductor and microelectronics thermal management solutions.
Keio Innovation Initiative (KII) is a venture capital established by Keio University. In order to make more effective use of the research results of Keio University, we aim to contribute to the development of society by creating investment for venture companies that utilize research results and creating new industries.The key to thinking aboutJapan's future growth strategy is to utilize advanced research results of the university. In addition to GDP, in addition to GDP, Japan is the world's third largest R & D exporter in R & D expenses, but as the low growth rate shows, it has a problem in investment efficiency in research and development. There are also reports on the entrepreneurial spirit that is indispensable for creating new industries, with the lowest entrepreneurial activity rate among developed countries.
Show more...Investment focus
- Industry: Health Care, Medical, Biotechnology
- Stage:Series A, Seed
- Geography: Japan, United Kingdom
Investor stats
- Total investments: 90
- Round size: Seed $826k–$50M; Series A $2.2M–$64M
- Lead/follow: 30% lead, 70% follow
- Last fund: May invest from a new fund soon — raised $1.4B in 2020
Portfolio highlights
- JiMED — JiMED designs & develops AI based brain-computer interface for implant in ALS patients to improve communication.
- Starlight Engine — Starlight Engine develops and commercializes fusion energy power plant technologies.
- Neusignal Therapeutics — Neusignal Therapeutics is a medical company that develops therapeutic medicines for dementia and psychiatric illnesses.
Goldport Capital is a Shenzhen-based asset management company.
Show more...Investment focus
- Industry: Manufacturing, Medical, Semiconductor
- Stage:Series A, Seed, Angel
- Geography: China
Investor stats
- Total investments: 71
- Round size: Seed $1.4M–$15M; Angel $425k–$14M; Series A $1.4M–$61M
- Lead/follow: 55% lead, 45% follow
Portfolio highlights
- Anxin Medical — Anxin Medical is a company dedicated to the research, development, production, and sales of innovative medical devices. The company focuses on advancing healthcare technology through continuous innovation, integrating cutting-edge science and engineering to create high-quality, reliable, and efficient medical products.
- SIYO Bio-Tech — SIYO Bio-Tech is a bioengineering company that focuses on research & innovation of microbial enzyme preparation technology.
- IS-Brain Technology — IS-Brain Technology is an AI-focused company developing robotic platform designed to enable robots to perceive, act autonomously.
Highlight Capital is an investment firm dedicated to support healthcare companies to generate robust and sustained growth prospect.
Show more...Investment focus
- Industry: Health Care, Medical, Biotechnology
- Stage:Series A, Series B, Seed
- Geography: China, United States, South Korea
Investor stats
- Total investments: 172
- Round size: Seed $10M–$84M; Series A $2.8M–$74M; Series B $7.6M–$70M
- Lead/follow: 34% lead, 66% follow
- Last fund: Likely still investing — raised $563M in 2021
Portfolio highlights
- Approaching.AI — Approaching.AI is an AI Infra company focusing on the important large model application scenarios such as RAG.
- PoShell Robotics — PoShell Robotics is a general-purpose home robot, aiming to create a home-friendly and structurally stable robot.
- Xingyuan Zongheng Network Technology — Beijing Xingyuan Zongheng Network Technology is an aerospace and satellite internet enterprise. The company focuses on high-tech satellite system development, constellation networking, and commercial operations.
SZHTI Group is a company that provides asset management and financing services.
Show more...Investment focus
- Industry: Manufacturing, Electronics, Semiconductor
- Stage:Series A, Angel
- Geography: China, United States
Investor stats
- Total investments: 132
- Round size: Angel $425k–$1.4M; Series A $780k–$16M
- Lead/follow: 29% lead, 71% follow
Portfolio highlights
- Elegoo — ELEGOO specializes in the research, development, and production of the most quality & affordable 3D printers, Arduino-based STEM & robotic kits, making technology easy-to-access for all the makers around the world.
- Menovex — Mir Medical Technology is a laser minimally invasive medical treatment enterprise, offering devices, core components, and modules in oral, urological, skin, and vascular fields. With independent research and development capabilities and international marketing, it provides full-cycle laser medical ODM services to domestic and foreign industrypartners.
- Yingshen Intelligence — Yingshen Intelligence is a robot developer that focuses in the research, growth, and application of embodied intelligence technology.
SBI Investment supports the business development and growth of private venture companies through fund investment. It manages and manages venture capital funds under the management philosophy of becoming a leading company responsible for the creation and development of core industries in the 21st century as a "new industry creator".SBIInvestment has invested in a total of 986 companies in the past, of which 169 (17.1% of investment companies) have exited through IPO or M & A.
Show more...Investment focus
- Industry: Software, Information Technology, Financial Services
- Stage:Series B, Series A
- Geography: Japan, South Korea, United States
Investor stats
- Total investments: 386
- Round size: Series A $2.3M–$142M; Series B $5.3M–$142M
- Lead/follow: 24% lead, 76% follow
- Last fund: May invest from a new fund soon — raised $1.1B in 2020
Portfolio highlights
- LQUOM — QWAVE offers cryptography communication technology.
- Alxtal — Alxtal is a tech company who optimize the development, design, and manufacturing processes of the manufacturing industry with IT and AI.
- Direava — Direava is a medical device company that manufactures, sells, leases, and maintains medical equipments along with consulting services.
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!Marathon Venture Partners is an international VC fund that focuses on early and growth stage companies in healthcare and Fintech industry.
Show more...Investment focus
- Industry: Health Care, Medical, Biotechnology
- Stage:Series A, Series B, Seed
- Geography: China, United States, Hong Kong
Investor stats
- Total investments: 63
- Round size: Seed $7M–$13M; Series A $1.4M–$16M; Series B $14M–$142M
- Lead/follow: 46% lead, 54% follow
Portfolio highlights
- Fungifuture — Fungifuture is a synthetic biomaterials company specializing in the research and development and production of fungal fiber materials.
- Ruize Health — Ruize Health is a commercial insurance company that focuses on health consumption and commercial insurance.
- Fuxin Technology Innovation — Fuxin Kechuang is a high-tech company that specializes in offering detailed information solutions for the medical and healthcare industries. The business offers creative software solutions and services to a range of healthcare organizations, actively supports the digital transformation of healthcare, and uplifts the medical sector. The company hasgained recognition and has become a partner of big and medium-sized medical institutions and healthcare institutions by relying on its technological research and development power, service capabilities, and ecosystem of medical and health software.
Shenzhen Capital Group Co., Ltd (“SCGC”) is a limited venture capital company established by the Shenzhen Government in 1999. Since its establishment, SCGC has focused on cultivating national industries, shaping national brands, promoting economic transformation, and emerging industries developing. SCGC has registered capital of 5.42 billion RMB,and a total AUM of 338.99 billion RMB. SCGC primarily invests in SMEs, innovative high-tech enterprises, enterprises in emerging industries, and enterprises in start-up period, growth period and in transformation, covering industries supported by national policies, including IT, internet, new media, biopharma, new energy, environmental protection, chemical engineering, new material, high-end equipment manufacturing, consumption goods, modern service, etc. By the end of April 2019, SCGC ranked the first based on the number of portfolio companies and the number of listed portfolio companies: 994 portfolio companies, investments totaling 43.9 billion RMB, 145 of which have been listed in 16 capital markets worldwide.
Show more...Investment focus
- Industry: Manufacturing, Health Care, Software
- Stage:Series A, Series B, Series C
- Geography: China, United States, Japan
Investor stats
- Total investments: 533
- Round size: Series A $1.6M–$156M; Series B $14M–$142M; Series C $4.3M–$156M
- Lead/follow: 40% lead, 60% follow
Portfolio highlights
- Prosemi — Pusenmei is a precision micro-resistance current sensor developer company committed to delivering professional and diverse precision micro-resistance current detecting resistors and circuit protection solutions.
- Enrikenuo — Enrikenuo is a biotechnology company that focuses on the research and development of new generation CAR-NK technology based cell drugs.
- Waker Biology — Weike Bio is a gene therapy drug development company.
Mizuho is the venture capital firm affiliated to Mizuho Bank, the second-largest Japanese bank in terms of assets. The firm has headquarters in Tokyo.The firm has ¥49.6 billion JPY under management, focusing on information technology and biotechnology investments. Over 600 Mizuho companies have gone public. According to Nikkei, Mizuho is thefifth-largest venture capital firm in Japan.Mizuho Capital was formed in 2002 by the merger of Fujigin Capital, Tokyo Venture Capital and IBJ Investment. Three firms were subsidiaries of Fuji Bank, Dai-Ichi Kangyo Bank and the Industrial Bank of Japan respectively.
Show more...Investment focus
- Industry: Information Technology, Software, Artificial Intelligence
- Stage:Series A, Series B
- Geography: Japan, United States, Singapore
Investor stats
- Total investments: 477
- Round size: Series A $2M–$79M; Series B $2.1M–$269M
- Lead/follow: 4% lead, 96% follow
- Last fund: May invest from a new fund soon — raised $1.4B in 2020
Portfolio highlights
- CaTe — CaTe is based in Tokyo. CaTe develops and manufactures a Digital Therapeutic (DTx) for remote cardiac rehabilitation. Their invention allows heart disease patients to safely and successfully complete cardiac rehabilitation utilizing standing exercise in a confined space, such as at home, without the use of ergometers or similar instruments.
- bestat — bestat is a developer of platforms for 3D data creation, management, and utilization using AI and offers digital twins services.
- FunPep — FunPep is an Industry-university collaboration bioventure company.
Huagai Capital is a private equity investment firm that invests in start-up or growth companies in the areas of healthcare, TMT, and culture.
Show more...Investment focus
- Industry: Health Care, Biotechnology, Medical
- Stage:Series A, Series B, Angel
- Geography: China, United States, Hong Kong
Investor stats
- Total investments: 143
- Round size: Angel $425k–$15M; Series A $1.4M–$67M; Series B $3.5M–$147M
- Lead/follow: 43% lead, 57% follow
- Last fund: May invest from a new fund soon — raised $430M in 2018
Portfolio highlights
- SeaArt — SeaArt AI is an all-in-one AI creativity community for art, videos, audio, and AI chats, where creators collaborate, spark inspiration, and grow together.
- GigaAI — Excellent Vision is a spatial intelligence company focused to transforming video creation into a 4D world model, enabling AI big models to grasp, generate, and reason about 4D space.
- Falcon Technology — Falcon Technology focuses on DSA processor design innovation, developing a dedicated computing technology ecosystem based on the RISC-V architecture to deliver high-performance, energy-efficient processing solutions for next-generation intelligent computing applications.
Shanlan Capital is a professional fund focused on early and growing health care industry investments with offices in Shanghai and Beijing, focusing on biomedical and medical devices (in vitro diagnostics and gene technology, minimally invasive interventions, implantable devices, minimally invasive High-growth segments such as surgical instrumentsand medical robots, and medical services. It has invested in 15 medical star companies such as Guoke Hengtai, Ricky Surgery, Jingyi Medical, Haipulos, Langhe Medical, etc. The core team of Shanlan Capital is the founder of the medical industry listed company, professional financial and strategic investment. Composition of people, in strategy formulation, talent introduction, technology research and development, market camp..
Show more...Investment focus
- Industry: Health Care, Medical, Medical Device
- Stage:Series A, Series B, Seed
- Geography: China
Investor stats
- Total investments: 35
- Round size: Seed $1.4M–$14M; Series A $1.4M–$16M; Series B $2.8M–$28M
- Lead/follow: 46% lead, 54% follow
Portfolio highlights
- Bochuang Biotechnology — Bochuang Biotechnology is a cutting-edge medical repair product developer that specializes in the controllable electrochemical assembly of biomacromolecules. Bochuang Biotechnology is creating a line of high-end biological tissue functional membranes and derived medical device solutions.
- Insight Technology — Insight Technology is an instrument manufacturer and seller company that specializes in instrument sales, intelligent instrument sales, mechanical equipment research and development, and more.
- Yangshan Medical Technology — Yangshan Medical Technology is a Shanghai-based company specializing in dental surgery robots.
Oriza Holdings is a Chinese management fund that covers equity, debt financing, and investment since 2007.
Show more...Investment focus
- Industry: Manufacturing, Health Care, Biotechnology
- Stage:Series A, Series B, Series C
- Geography: China, United States, Canada
Investor stats
- Total investments: 205
- Round size: Series A $1.7M–$55M; Series B $10M–$100M; Series C $14M–$200M
- Lead/follow: 26% lead, 74% follow
Portfolio highlights
- ChipSine — ChipSine is an Integrated Circuit (IC) design company that focuses on the research and development of automotive-grade electronic control chips.
- Empower — Empower is an enterprise platform focused on intelligent laser manufacturing that makes lasers smart.
- Neowise — XinjingZhiyuan is an immune cell therapy company focusing on solid tumors.
Nippon Venture Capital ("NVCC"), established in 1996 as one of the few largest Japanese independent venture capital firms, is destined to undertake the unprecedented task of providing full-range venture capital services in cooperation with major Japanese business leaders and leading companies, which have supported and nurtured various newbusinesses on their own, as well as proactively developing new venture enterprises.
Show more...Investment focus
- Industry: Software, Health Care, Information Technology
- Stage:Series A, Series B
- Geography: Japan, United States, Indonesia
Investor stats
- Total investments: 172
- Round size: Series A $1.5M–$74M; Series B $3.3M–$269M
- Lead/follow: 15% lead, 85% follow
- Last fund: Likely still investing — raised $278M in 2023
Portfolio highlights
- Space BD — Space BD aims to become a one-stop shop to respond to all issues related to industrialization of space, and alleviate the work of businesses that are developing new technologies.
- KUZEN — KUZEN provides enterprise-grade chatbot technologies, especially the bot framework and NLP, via a visual UI without coding. The company is utilizing technology to develop a system that broadens the scope of dialogue. They use technology to provide their customers with next-generation standard procedures that broaden the possibilities ofconversation, resulting in unprecedented business practices.
- Neusignal Therapeutics — Neusignal Therapeutics is a medical company that develops therapeutic medicines for dementia and psychiatric illnesses.
ANRI is a Japanese venture capital firm that mainly invests in seed and early-stage startups.
Show more...Investment focus
- Industry: Software, Medical, Health Care
- Stage:Seed, Series A
- Geography: Japan, United States, Indonesia
Investor stats
- Total investments: 269
- Round size: Seed $413k–$19M; Series A $2.3M–$41M
- Lead/follow: 23% lead, 77% follow
- Last fund: Likely still investing — raised $102M in 2022
Portfolio highlights
- Any Style — Any Style develops a messaging app from voice actors that regularly sends messages via subscription. It also engages in the planning and production of audio content and the VTuber production business.
- Chaintope — Chaintope is specializes in blockchain technology with a focus for FinTech and non-FinTech sectors.
- Smile Robotics — Smile Robotics provides Service Robots in Japan.
CDH Investments is an international alternative asset fund manager with over $27 billion of assets under management. CDH Investments was established in 2002 by the former private equity group of China International Capital Corporation and is managed by an experienced team of senior private equity professionals who have worked together for manyyears focusing all their professional time on investing in China. CDH has consistently delivered superior returns relative to industry peers and is well positioned to continue to generate superior returns due to the team's proven investment experience and expertise investing in China.
Show more...Investment focus
- Industry: Manufacturing, Health Care, Biotechnology
- Stage:Series A, Series B, Series C
- Geography: China, United States, Canada
Investor stats
- Total investments: 298
- Round size: Series A $7.3M–$100M; Series B $14M–$142M; Series C $30M–$220M
- Lead/follow: 47% lead, 53% follow
Portfolio highlights
- HitGen — HitGen is provides biological reagents and services to support drug discovery research.
- PaXini Tech — All Scenario Application—Haptic Digitization and Tactile Technology
- Eyegood Ophthalmic Hospital — Eyegood Ophthalmic Hospital is a ophthalmology hospital.
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!Fortune Capital, established in April, 2000, is one of the earliest market-oriented venture capital firms in China. For the past 14 years, Fortune Capital focus its investments on leading companies in four key sectors: TMT (Media oriented), Consumer Goods/Services, Modern Agriculture and Clean Tech.Fortune Capital is ranked among thehighest performing VC/PE firms in China and selected as "Vice President of Venture Capital Committee of IAC," "Vice President of Shenzhen VC Association," "Vice President of Shenzhen Chamber of International Investment & Funding," etc.In addition to providing capitals, Fortune Capital provides its investee companies with personalized value-added services.
Show more...Investment focus
- Industry: Manufacturing, Software, Information Technology
- Stage:Series A, Series B, Seed
- Geography: China, Japan, United States
Investor stats
- Total investments: 283
- Round size: Seed $425k–$73M; Series A $1.4M–$70M; Series B $2.8M–$57M
- Lead/follow: 40% lead, 60% follow
- Last fund: May invest from a new fund soon — raised $780M in 2021
Portfolio highlights
- Sandstone — SandStone is a product, solution and service provider focused on next-generation data storage (ServerSAN), which is dedicated to helping users cope with data storage, traffic and data management complexity, helping users build storage virtualization and Computation of virtualization as the core cloud computing infrastructure environment, andgradually provide data processing, mining, analysis and intelligence in the field of big data professional systems and services.
- Xinjie Energy — Xinjie Energy focuses on the research, development, and production of lithium metal solid-state batteries. These batteries aim to offer energy density and improved safety compared to traditional lithium-ion batteries. The company works on advancing battery technology, with potential applications in electric vehicles and energy storage. It isinvolved in advancing solid-state battery technology and expanding its presence in the battery industry.
- Strongest Laser — Strongest Laser is a high-power fiber laser equipment developer.
Apricot Capital is an investment firm focused on investing in companies in the early and growing stages of the healthcare industry, including biopharmaceuticals, life sciences, medical devices, medical services, and diagnostics.Founded in 2015, Apricot Capital consists of more than 20 professionals and consultants with experience in thehealthcare industry. Its professional background includes life sciences, medicine, finance and law.
Show more...Investment focus
- Industry: Biotechnology, Health Care, Medical
- Stage:Series A, Seed, Series B
- Geography: China, United States, Hong Kong
Investor stats
- Total investments: 46
- Round size: Seed $10M–$41M; Series A $3M–$54M; Series B $14M–$58M
- Lead/follow: 50% lead, 50% follow
Portfolio highlights
- iRegene — iRegene researches and develops pharmaceutical therapy for neurodegenerative and rare diseases.
- Vibrant — Vibrant develops an AI drug development platform to focus on building immune system-related drug pipelines. The company will use artificial intelligence algorithms to accelerate the efficiency of drug development in various aspects such as target discovery, drug design, and drug efficacy evaluation; at the same time, the company expects tocontinuously improve the success rate of drug development through sustainable data accumulation and algorithm optimization.It was founded and headed by Dr. Wang Luquan and is based in Guangzhou, Guangdong, China.
- Microtide Biotechnology — Microtide Biotechnology is an innovative company specializing in the field of in vivo cell therapy. The company is dedicated to advancing next-generation biomedical technologies that harness the body’s own cellular mechanisms for disease treatment, focusing on developing safe, effective, and precise therapeutic solutions to improve patient outcomesand redefine the future of regenerative medicine.
UTEC-The University of Tokyo Edge Capital Partners Co., Ltd.. UTEC is a seed/early stage technology focused venture capital firm associated with The University of Tokyo.
Show more...Investment focus
- Industry: Health Care, Biotechnology, Medical
- Stage:Seed, Series A, Series B
- Geography: Japan, United States, India
Investor stats
- Total investments: 195
- Round size: Seed $2.5M–$35M; Series A $2.8M–$64M; Series B $2.8M–$100M
- Lead/follow: 35% lead, 65% follow
Portfolio highlights
- Flosfia — FLOSFIA is a spin-off from a research of Kyoto University, specializing in film-formation by mist chemical vapor deposition (CVD). Making use of physical properties of gallium oxide (Ga2O3), FLOSFIA has devoted to development of low-loss power devices.
- TXP Medical — TXP Medical build a next-generation medical system through acute care.
- Startbahn — Startbahn aims to realize a richer society by providing the technology needed by artists and people involved with art all over the world. We are developing Startbahn Cert., a service that issues blockchain certificates for artworks, and promoting the development of Startrail, a blockchain infrastructure that is the basis for Startbahn Cert. We alsorun joint projects with other companies.
Tsinghua Innovation Ventures is an investment management firm.
Show more...Investment focus
- Industry: Manufacturing, Medical, Health Care
- Stage:Series A, Seed
- Geography: China
Investor stats
- Total investments: 94
- Round size: Seed $832k–$15M; Series A $1.4M–$23M
- Lead/follow: 21% lead, 79% follow
Portfolio highlights
- Huayuan Zhiyin — Huayuan Zhiyin focuses on AI Virtual Cell and life science-native technologies.
- FangQing Technology — Fangqing Technology is a company mainly engaged in multiple areas of the communications equipment and software industry. Its core business activities include software development and sales, software outsourcing services, information system integration services, and computer system services.
- Starlink Innovation — Starlink Innovation makes satellite communication terminals, space-ground communication hardware and software, and satellite applications.
Catalysing smart monies into Singapore-based, early-stage technology startups.
Show more...Investment focus
- Industry: Biotechnology, Artificial Intelligence, Health Care
- Stage:Seed, Series A, Series B
- Geography: Singapore, United States, Hong Kong
Investor stats
- Total investments: 146
- Round size: Seed $767k–$6M; Series A $2.4M–$21M; Series B $5M–$45M
- Lead/follow: 19% lead, 81% follow
Portfolio highlights
- Pints AI — Unlock global and private financial data with AI like never before.
- ChemT Biotechnology — The goal of ChemT Biotechnology is to increase patient access to the most cutting-edge biologics, beginning with the urgent issues in manufacturing and research and development.
- Protuoso Biosciences — Protuoso Bio is a pioneering biotechnology company developing Next-Gen MUXBODIES for Complex Diseases. We leverage AI-driven protein engineering and synthetic biology to advance innovative oncology drug research.
Nissay Capital is a venture capital Company specializing in seed, start-up, growth capital, middle stage, and later stage investment.
Show more...Investment focus
- Industry: Health Care, Information Technology, Medical
- Stage:Seed, Series A
- Geography: Japan, United States, Ethiopia
Investor stats
- Total investments: 264
- Round size: Seed $565k–$43M; Series A $2M–$71M
- Lead/follow: 25% lead, 75% follow
Portfolio highlights
- Welyco — Welyco is an information technology company.We operate smart restaurant "solto". Utilize IT to realize efficient and diverse restaurant management.
- Toranotec — TORANOTEC CORPORATION aims to create a world where investment is familiar to everyone by realizing "from consumption to investment" through the services of asset management subsidiaries , utilizing advanced technology.
- Zeal Boxing Fitness — Zeal Boxing Fitness combines power of sports with the power of technology to provide a service that allows to enjoy fitness.
Huaige Capital is a venture capital focusing on healthcare sector.
Show more...Investment focus
- Industry: Medical, Health Care, Biotechnology
- Stage:Series A, Angel, Seed
- Geography: China
Investor stats
- Total investments: 23
- Round size: Angel $425k–$14M; Series A $2.8M–$36M
- Lead/follow: 30% lead, 70% follow
Portfolio highlights
- Heerkang — Heerkang is a medical technology company that provides medical device research and sales, and health consultation services.
- Xianyan Biopharma — Xianyan Biopharma is a company that focuses on core technology innovation and new medication development for oligonucleotides, and it has a top-tier R&D staff.
- Yili Pharmaceutical — Yili Pharmaceutical is a pharmaceutical R&D company that mainly engages in biochemical product technology R&D, medical research and experimental development, engineering and technology research and experimental development, and software development.
Supporting the next generation of entpreneurs in enterprise, healthcare, and consumer with disruptive potential.
Show more...Investment focus
- Industry: Health Care, Medical, Biotechnology
- Stage:Series A, Series B, Seed
- Geography: China, United States, South Korea
Investor stats
- Total investments: 274
- Round size: Seed $1.3M–$100M; Series A $4.3M–$67M; Series B $11M–$62M
- Lead/follow: 27% lead, 73% follow
- Last fund: Likely still investing — raised $375M in 2021
Portfolio highlights
- Flytech — Flytech specializes in crystal materials and related components for magneto-optical-electrical integrated signal processing.
- Moge Microflow — Moge Microflow is a manufacturer of equipment for microreactors. It provides continuous flow production technologies and equipment for nanomaterials, pharmaceutical intermediates, and fine chemicals, as well as standardized high-end microreactor equipment.
- Bianzhong New Materials — Bianzhong New Materials is a high-tech company that specializes in the research and development of equipment for weaving and shaping three-dimensional preforms of high-strength fiber composite materials.
FFG Venture Business Partners is a large-scale enterprise that offers in traditional regional bank venture capital.
Show more...Investment focus
- Industry: Software, Health Care, Artificial Intelligence
- Stage:Series A, Seed, Series B
- Geography: Japan, Indonesia, United States
Investor stats
- Total investments: 87
- Round size: Seed $1M–$50M; Series A $1.2M–$37M; Series B $4.3M–$113M
- Lead/follow: 10% lead, 90% follow
- Last fund: May invest from a new fund soon — raised $691M in 2020
Portfolio highlights
- MW — MW is a smart home solution company that develops smart residential physical AI, robotics, and home design services.
- InsightX — InsightX is a technology platform focused on empowering businesses by simplifying complex processes and enabling smarter, more personalized user experiences.
- Neusignal Therapeutics — Neusignal Therapeutics is a medical company that develops therapeutic medicines for dementia and psychiatric illnesses.
Shenzhen Green Pine Capital Partners Co. Ltd. (“GPCP”) was established in 2007, with the investment team assembled in 2000. GPCP is one of the most time-honored Chinese VC companies that boast experience in areas such as biotech, new materials, new resources and AI, etc. Currently, GPCP manages assets over 15 billion RMB through 21 special fundsand have invested 7 billion RMB into 388 enterprises among which 14 are listed on NEEQ and 48 of them are either listed or acquired by listed companies, including BGI(300676.SZ), Aurora(600666.SH), Nationz Tech(300077.SZ), Foresee(002530.SZ), Qudian(NASDAQ:QD), etc. GPCP invested in the angel round of BGI (Beijing Genomics Institute), Royole, Kuang-Chi, Appotronics, BMF, C-one, Arrayed Materials and other star enterprises.GPCP is based in Shenzhen, with branches in Beijing, Shanghai and Guangzhou. GPCP also runs two GPI incubators and an incubator for overseas Chinese scientists who start businesses in China.
Show more...Investment focus
- Industry: Artificial Intelligence, Biotechnology, Health Care
- Stage:Series A, Angel, Series B
- Geography: China, United States, Canada
Investor stats
- Total investments: 192
- Round size: Angel $425k–$2.9M; Series A $1.4M–$92M; Series B $9.9M–$150M
- Lead/follow: 33% lead, 67% follow
- Last fund: May invest from a new fund soon — raised $138M in 2019
Portfolio highlights
- FutureFab.AI — Zhixian Future is a provider of engineering intelligent system solutions driven by multi-modal large models, serving more than 180 benchmark semiconductor customers.
- Sungen Biomedical — Sungen Biomedical is engaged in the development of first-in-class (FIC) antibody therapeutics.
- Signet Therapeutics — Signet Therapeutics is a cutting-edge firm that conducts research and development on cancer-targeted drugs using AI and organoid disease models.
FAQ
Is Shizune data fresh/accurate?
Shizune has monitored hundreds of funding sources since 2020.
Our investor database is updated every day, so investor data is always fresh.
All metrics are calculated from confirmed public rounds, so the data is accurate.
Can I download investor list?
To download the Medical Device VC Funds in Asia investor list, create a Shizune account. This investor list will be added to your saved investors and available for download in the export section.
You can also enrich the investor list with investor emails, phones, LinkedIns, and other contact data.
Can I access investor database?
To access all 48,091 VC funds investing in Asia Medical Device startups and 48,091+ more investors, create a Shizune account.
Shizune has a database of 48,091 investors. Our investor database is fresh and updated daily.
The Shizune investor database has information on investor investment focus, investor contact data, and full investor portfolio since 2020.
You can enrich with email and download the data.
Does Shizune have investor emails and contacts?
Shizune enriches investors with contact data that includes: email, phones, LinkedIn, socials, website, and others.
To guarantee the highest discovery rate, we search across 20+ contact search tools.
To maximize delivery rate and reduce bounce rate, we validate emails.
You can enrich your investor list with Shizune. Download it too.
What is Shizune?
Shizune is a 48,091 investor database updated daily.
With Shizune you can:
- browse the database
- use smart matching
- enrich with emails
- download
All you need to find investors for your startup.
Who is Shizune for?
Shizune is built for startup founders by startup founders.
If you are looking for funding for your startup, try the Shizune database — we have investors for every stage, industry, and country.
Is Shizune free?
Shizune is free forever. You can search and browse investors for free.
Email search and export are paid features.
For full info, visit our pricing.
Who built Shizune?
Shizune is built by founders with the goal of helping all founders raise funding no matter where they are.
Contact 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!